Biochemical, neuropathological, and neuroimaging characteristics of early-onset Alzheimer's disease due to a novel PSEN1 mutation

Neuroscience Letters

Volumn 487, Issue 3, 2011, Pages 287-292

  Ringman, John M ^a   Gylys, Karen H ^a   Medina, Luis D ^a   Fox, Michelle ^a   Kepe, Vladimir ^a   Flores, Deborah L ^b   Apostolova, Liana G ^a   Barrio, Jorge R ^a   Small, Gary ^c   Silverman, Daniel H ^a   Siu, Erin ^a   Cederbaum, Stephen ^a,c   Hecimovic, Silva ^d   Malnar, Martina ^d   Chakraverty, Suma ^e   Goate, Alison M ^e   Bird, Thomas D ^f   Leverenz, James B ^f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HARBOR UCLA MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d RUDER BO KOVI INSTITUTE   (Croatia)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Alzheimer's disease; Amyloid imaging; Beta amyloid; Cerebrospinal fluid; FDDNP; FDG; Positron emission tomography; PSEN1; S212Y; Striatum; Tau

Indexed keywords

AMYLOID BETA PROTEIN; FLUORODEOXYGLUCOSE F 18; MEMBRANE PROTEIN; PROTEIN PSEN1; TAU PROTEIN; UNCLASSIFIED DRUG;

ADULT; ALZHEIMER DISEASE; ARTICLE; BRAIN METABOLISM; CASE REPORT; CEREBROSPINAL FLUID ANALYSIS; CORPUS STRIATUM; DEPTH PERCEPTION; DIAGNOSTIC IMAGING; FEMALE; GENE MUTATION; GENETIC ANALYSIS; HUMAN; IN VITRO STUDY; MEMORY DISORDER; NEUROIMAGING; NEUROPATHOLOGY; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; PARIETAL CORTEX; PEDIGREE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; TEMPORAL CORTEX;

ADULT; AGE OF ONSET; ALZHEIMER DISEASE; BRAIN; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; NEUROPSYCHOLOGICAL TESTS; PEDIGREE; POSITRON-EMISSION TOMOGRAPHY; PRESENILIN-1;

EID: 78650523170     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2010.10.039     Document Type: Article

References (19)

1. Berezovska O., Lleo A., Herl L.D., Frosch M.P., Stern E.A., Bacskai B.J., Hyman B.T. Familial Alzheimer's disease presenilin 1 mutations cause alterations in the conformation of presenilin and interactions with amyloid precursor protein. J. Neurosci. 2005, 25:3009-3017.
2. Cole G.B., Keum G., Liu J., Small G.W., Satyamurthy N., Kepe V., Barrio J.R. Specific estrogen sulfotransferase (SULT1E1) substrates and molecular imaging probe candidates. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:6222-6227.
3. Fagan A.M., Head D., Shah A.R., Marcus D., Mintun M., Morris J.C., Holtzman D.M. Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Ann. Neurol. 2009, 65:176-183.
4. Hardy J., Crook R. Presenilin mutations line up along transmembrane alpha-helices. Neurosci. Lett. 2001, 306:203-205.
5. Hecimovic S., Wang J., Dolios G., Martinez M., Wang R., Goate A.M. Mutations in APP have independent effects on Abeta and CTFgamma generation. Neurobiol. Dis. 2004, 17:205-218.
6. Lee P., Medina L., Ringman J.M. The Thr354Ile substitution in PSEN1: disease-causing mutation or polymorphism?. Neurology 2006, 66:1955-1956.
7. Lopera F., Ardilla A., Martinez A., Madrigal L., Arango-Viana J.C., Lemere C.A., Arango-Lasprilla J.C., Hincapie L., Arcos-Burgos M., Ossa J.E., Behrens I.M., Norton J., Lendon C., Goate A.M., Ruiz-Linares A., Rosselli M., Kosik K.S. Clinical features of early-onset Alzheimer disease in a large kindred with an E280A presenilin-1 mutation. JAMA 1997, 277:793-799.
8. Mungas D., Reed B.R., Crane P.K., Haan M.N., Gonzalez H. Spanish and English Neuropsychological Assessment Scales (SENAS): further development and psychometric characteristics. Psychol. Assess. 2004, 16:347-359.
9. Murrell J., Ghetti B., Cochran E., Macias-Islas M.A., Medina L., Varpetian A., Cummings J.L., Mendez M.F., Kawas C., Chui H., Ringman J.M. The A431E mutation in PSEN1 causing Familial Alzheimer's Disease originating in Jalisco State, Mexico: an additional fifteen families. Neurogenetics 2006, 7:277-279.
10. Pastor P., Roe C.M., Villegas A., Bedoya G., Chakraverty S., Garcia G., Tirado V., Norton J., Rios S., Martinez M., Kosik K.S., Lopera F., Goate A.M. Apolipoprotein Eepsilon4 modifies Alzheimer's disease onset in an E280A PS1 kindred. Ann. Neurol. 2003, 54:163-169.
11. Ringman J.M., Diaz-Olavarrieta C., Rodriguez Y., Chavez M., Paz F., Murrell J., Macias M.A., Hill M., Kawas C. Female preclinical presenilin-1 mutation carriers unaware of their genetic status have higher levels of depression than their non-mutation carrying kin. J. Neurol. Neurosurg. Psychiatry 2004, 75:500-502.
12. Ringman J.M., Younkin S.G., Pratico D., Seltzer W., Cole G.M., Geschwind D.H., Rodriguez-Agudelo Y., Schaffer B., Fein J., Sokolow S., Rosario E.R., Gylys K.H., Varpetian A., Medina L.D., Cummings J.L. Biochemical markers in persons with preclinical familial Alzheimer disease. Neurology 2008, 71:85-92.
13. Shaw L.M., Vanderstichele H., Knapik-Czajka M., Clark C.M., Aisen P.S., Petersen R.C., Blennow K., Soares H., Simon A., Lewczuk P., Dean R., Siemers E., Potter W., Lee V.M., Trojanowski J.Q. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann. Neurol. 2009, 65:403-413.
14. Small G.W., Kepe V., Ercoli L.M., Siddarth P., Bookheimer S.Y., Miller K.J., Lavretsky H., Burggren A.C., Cole G.M., Vinters H.V., Thompson P.M., Huang S.C., Satyamurthy N., Phelps M.E., Barrio J.R. PET of brain amyloid and tau in mild cognitive impairment. N. Engl. J. Med. 2006, 355:2652-2663.
15. Vanderstichele H., Van Kerschaver E., Hesse C., Davidsson P., Buyse M.A., Andreasen N., Minthon L., Wallin A., Blennow K., Vanmechelen E. Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma. Amyloid 2000, 7:245-258.
16. Villemagne V.L., Ataka S., Mizuno T., Brooks W.S., Wada Y., Kondo M., Jones G., Watanabe Y., Mulligan R., Nakagawa M., Miki T., Shimada H., O'Keefe G.J., Masters C.L., Mori H., Rowe C.C. High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types. Arch. Neurol. 2009, 66:1537-1544.
17. Wallin A.K., Blennow K., Zetterberg H., Londos E., Minthon L., Hansson O. CSF biomarkers predict a more malignant outcome in Alzheimer disease. Neurology 2010, 74:1531-1537.
18. Wijsman E.M., Daw E.W., Yu X., Steinbart E.J., Nochlin D., Bird T.D., Schellenberg G.D. APOE and other loci affect age-at-onset in Alzheimer's disease families with PS2 mutation. Am. J. Med. Genet. B: Neuropsychiatr. Genet. 2005, 132B:14-20.
19. Wong K.P., Wardak M., Shao W., Dahlbom M., Kepe V., Liu J., Satyamurthy N., Small G.W., Barrio J.R., Huang S.C. Quantitative analysis of [18F]FDDNP PET using subcortical white matter as reference region. Eur. J. Nucl. Med. Mol. Imaging. 2010, 37:575-588.